ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.
BioTechniques

Unmasking angiogenesis and the tumor microenvironment with Douglas Hanahan

Douglas Hanahan (left), the former Director of the Swiss Institute for Experimental Cancer Research (ISREC) at EPFL, works in the Agora Translational Cancer Research Center as a member of the Ludwig ...
BioWorld

Next-generation inhibitors of PDGFR-α in cancer

Excessive signaling by platelet-derived growth factor receptor (PDGFR)-α, a transmembrane tyrosine kinase, helps drive the ...
Scientific Research Publishing

Research Progress and Prospects on Biomarkers for Endometrial Cancer and New Targets for Precision Diagnosis and Treatment ()

Research Progress and Prospects on Biomarkers for Endometrial Cancer and New Targets for Precision Diagnosis and Treatment ...
EurekAlert!

Beyond traditional treatment: Scientists explore integrating stress management into cancer care

Chronic stress fuels cancer by releasing stress mediators that remodel the tumor and stromal cells, promoting immune evasion, angiogenesis, and metastasis. A review in Science Bulletin underscores how ...

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation ...

GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the ...